Cataract is a multifactorial disease with increasing prevalence with age. Adult diabetics develop cataract earlier. Lens epithelial cells (LECs) exposed to oxidative stress (ROS), increased calcium deposit and membrane damage, undergo apoptosis, which results in lens opacification. Remaining LECs post-surgery leads to posterior capsular opacification (PCO). This study’s aim was to investigate the physiological characteristics of LECs from cataractous diabetic and non-diabetic lenses. Leader cells migration from age-related cataracts started on day 5–7 and from type-2 diabetics on day 8–10. Differences were found in the collective migratory activity and colony formation. On day 22, the colonies formed by LECs from age-related cataracts were three times more, than those formed by diabetic LECs. DNA synthesis and FOXM1 expression occurred in 55.76% of age-related cataract LECs, but only in 33.45% of diabetic LECs. The highest level of reactive oxygen species (ROS) was found in diabetic LECs. Extracellular matrix calcification followed the same pattern as ROS. Among the main reasons for the development of age-related and diabetic cataracts is lens damage due to ROS release and elevated calcium levels. Diabetic LECs experience significantly lower in vitro migration and proliferative activities, compared to LECs from age-related cataracts. This is the first study of its kind in Bulgaria, contributing to the elucidation of the mechanisms of primary and secondary cataractogenesis in diabetic and non-diabetic adults.
Ocular drug delivery (topical or intraocular) is hindered by physiological barriers, including the mucus layer, surface epithelium, tear drainage, enzyme metabolism, and the blood–aqueous and blood–retina barriers. Conventional dosage forms face problems related to short retention time and poor drug bioavailability. The development of nanoparticles as drug delivery systems is an advantageous strategy that could overcome these limitations. Nanoparticles can prolong the retention time on the ocular surface, allowing more effective contact with the epithelium. In addition, they can reduce the side effects of drugs due to their capability to release the drug at a desired rate. Finally, nanoparticles can improve the solubility of poorly water-soluble drugs, further enabling their absorption. The present review summarizes recent research on the development of three types of nanoparticles as carriers for ophthalmic drug delivery, particularly polymeric micelles, nanogels, and nanocrystals.
This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.
The review focuses on recent achievements regarding the implementation of lipid-based nanoparticles for topical ocular delivery. Lipid-based nanoparticles are very attractive because the carriers themselves provide several advantages. For example, some of the lipid ingredients could increase drug absorption because of their high affinity for cell membranes, whereas other lipid ingredients could function as permeation enhancers. Furthermore, their capacity to provide longer residence time and sustained drug release makes them effective systems capable of overcoming rapid drug elimination via nasolacrimal drainage and tear turnover. The review discusses the advantages and properties of liposomes, cubosomes, and solid lipid nanoparticles in detail. Various examples of the influence of the characteristics of these particles (e.g., mean diameter, surface charge, and structure) on their behavior after topical ocular instillation are included in the respective sections.
Retinopathy of prematurity (ROP) is one of the most serious eye diseases affecting prematurely born infants. Modern treatment methods, including laser photocoagulation, have significantly reduced the incidence of blindness and severe visual impairment due to tractional retinal detachment, macular folds, or excessive myopia. However, long-term complications are still observed in some patients, among which cataract formation holds particular significance. The aim of this study was to evaluate the risk of cataract development in premature infants treated for type 1 ROP. We performed a retrospective study during which we studied 660 premature infants (352 boys and 308 girls) for a period of 5 years. Of these, 145 children (21.97%) were diagnosed with ROP at different stages. A total of 97 children (66.9% of those with ROP) underwent treatment for type 1 ROP. Of these, 80 were treated with laser photocoagulation, and 17 with intravitreal anti-VEGF medications. In the remaining 48 children, spontaneous regression of the disease occurred, and no treatment was necessary. During the study period, only one child (1.25%) developed a cataract. The proper balance between laser energy and number of laser spots is crucial for avoiding complications such as cataract formation. Laser therapy for ROP saves the vision of thousands of children worldwide, but it carries a risk of later complications, including cataract formation. Early detection, along with appropriate surgical treatment, optical correction, and occlusion therapy, is crucial for amblyopia prevention and normal visual development. These patients require long-term follow-up and multidisciplinary care to ensure maximum visual potential.
The management of ocular hypertension and the various forms of glaucoma during pregnancy and lactation represents a significant clinical challenge. The main concerns are related to the selection of an appropriate therapeutic strategy, with special attention paid to the risks associated with treatment for both the mother and the fetus or breastfed infant. There is no universally accepted management protocol for these patients. Owing to the understandable lack of randomized clinical trials in this population, there is currently no officially approved antiglaucoma medication for use during pregnancy or breastfeeding. Selective laser trabeculoplasty is an excellent option for reducing intraocular pressure during pregnancy and lactation, particularly in view of its favorable safety profile. Two clinical cases of patients with ocular hypertension and elevated intraocular pressure who underwent selective laser trabeculoplasty are presented. A sustained and significant reduction in intraocular pressure was achieved. In both cases, the need for antiglaucoma medication was eliminated throughout the follow-up period.